Published in final edited form as:

J Alzheimers Dis. 2015 ; 48(3): 731–743. doi:10.3233/JAD-150318.

Tomoregulin (TMEFF2) Binds Alzheimer's Disease Amyloid- β ($A\beta$) Oligomer and $A\beta$ PP and Protects Neurons from $A\beta$ -Induced Toxicity

Hyun-Seok Hong^{a,1}, Izumi Maezawa^{a,b,c}, Jitka Petrlova^{d,2}, Xiao-Yan Zhao^e, John C. Voss^d, and Lee-Way Jin^{a,b,c,*}

^aDepartment of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA

^bAlzheimer's Disease Center, University of California Davis Medical Center, Sacramento, CA, USA

^cM.I.N.D. (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis Medical Center, Sacramento, CA, USA

^dDepartment of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA, USA

^eBiologics Research-USIC, Bayer Healthcare Pharmaceuticals, San Francisco, CA, USA

Abstract

Amyloid- β ($A\beta$) protein causes neurotoxicity and its abnormal aggregation into amyloid is a pathological hallmark of Alzheimer's disease (AD). Cellular proteins able to interact with $A\beta$ or its precursor, $A\beta$ PP (amyloid- β protein precursor), may regulate $A\beta$ production and neurotoxicity. We identified a brain-enriched type I transmembrane protein, tomoregulin (TR), that directly binds $A\beta$ and $A\beta$ oligomers ($A\beta$ O). TR co-immunoprecipitated with $A\beta$ and $A\beta$ O in cultured cells and co-localized with amyloid plaques and intraneuronal $A\beta$ in the 5xFAD AD mouse model. TR was also enriched in astrocytic processes reactive to amyloid plaques. Surface plasmon resonance spectroscopy studies showed that the extracellular domain of TR binds to $A\beta$ O with a high affinity ($K_D = 76.8$ nM). Electron paramagnetic resonance spectroscopy also demonstrated a physical interaction between spin-labeled $A\beta$ and the TR extracellular domain in solution. Furthermore, TR also interacted with $A\beta$ PP and enhanced its cleavage by α -secretase. Both cellular expression of TR and application of recombinant TR extracellular domain protected N2a neurons from $A\beta$ O-induced neuronal death. These data provide first evidence that neuronal and astrocytic expression of TR is intimately related to $A\beta$ metabolism and toxicity, and could be neuroprotective through its direct interaction with $A\beta$ and $A\beta$ PP.

*Correspondence to: Lee-Way Jin, MD, PhD, Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA. Tel.: +1 916 703 0392; Fax: +1 916 703 0370; lwjin@ucdavis.edu.

¹Present address: Medifron-DBT, Inc., Sandnaro 349, Danwongu, Ansan-si, Gyeonggi-do, Korea.

²Present address: BMC B14, Department of Experimental Medical Science, Lund University, Lund, Sweden.

Keywords

Alzheimer's disease; amyloid; binding; neuroprotection; neurotoxicity; tomoregulin

INTRODUCTION

Amyloid- β (A β), a amphipathic protein derived from proteolytic processing of the amyloid- β protein precursor (A β PP), self aggregates into amyloid fibrils and deposits as amyloid plaques, one of the pathological hallmarks of AD. Although quite heterogeneous at its carboxyl termini, A β peptides have been characterized based on two major forms, A β_{1-40} and A β_{1-42} [1]. In addition to fibrillar forms, A β exists in various smaller assemblies in AD brains, which may mediate diverse toxic effects at different stages of the disease. Although these smaller aggregates, variously named as oligomers (A β O), protofibrils, amyloid pores, or AD diffusible ligands, have been considered transient or metastable intermediates in fibril formation [2], some of them may not be obligate intermediates in the fibril formation pathway and can be stable [3, 4]. Importantly, *in vitro* and *in vivo* studies have revealed that the build-up of soluble A β O may be an early and central event in the pathogenesis of AD [5–8]. The strong and rapidly disruptive effect of A β O on synaptic plasticity and neuronal integrity is hypothesized to cause memory problems in AD [6, 7, 9–11]. Initial oligomerization of A β appears to occur intraneuronally [12]; extracellular A β O could be derived from intraneuronal A β O [12, 13]. It is therefore conceivable that during the process of A β O formation, release, and cellular targeting, several proteins may interact with A β O to regulate or mediate its aggregation, transport, diffusion, and action on cells, thereby modifying its toxicity.

In an effort to seek potential endogenous modifiers of A β toxicity, we discovered a protein, tomoregulin (TR), that is able to bind A β O and inhibit its toxicity. TR, also named TMEFF2, TENB2, TPEF, and HPP1, is a type I transmembrane protein expressed in embryo but only selectively expressed in adult nervous system and prostate. It contains a short cytoplasmic tail and a unique extracellular region (ectodomain) with one epidermal growth factor-like motif and two follistatin-like domains (Fig. 1). The ectodomain is released by a membrane-anchored metalloproteinase ADAM17, and could be a ligand for erbB-4- or erbB-4-related receptor tyrosine kinase [14, 15]. TR is widely expressed in the central and peripheral nervous systems as well as by the enteric neurons of the gastrointestinal tract [16, 17]. Despite its selective expression pattern, the physiological and pathological roles of TR in the brain remain little studied. Here we report that TR could be an endogenous modulator of A β O actions including its toxicity. In addition, TR is associated with cellular A β PP and enhances the generation of a secreted form of A β PP released by α -secretase.

MATERIALS AND METHODS

Materials

The polyclonal antibody against full-length, recombinant TR was obtained from R&D System. Mouse monoclonal antibody 48G2 was raised against the recombinant human TR using hybridoma technology at Bayer Healthcare Pharmaceuticals (San Francisco, CA).

Surface plasmon resonance spectroscopy (SPR) showed that 48G2 in the flow phase bound immobilized TR with a high affinity ($K_D = 0.88$ nM). The affinity is comparable to a TR-specific monoclonal antibody 2H8 ($K_D = 1.24$ nM), which was previously characterized extensively [18]. In an ELISA assay, 48G2 bound TR with an EC_{50} value of 0.17 nM, but showed minimal binding to human TMEFF1, a TR-related protein [19]. Furthermore, 48G2 bound to the surface of human TR-transfected PC-3 (human prostatic cancer) cells, assessed by fluorescence-activated cell sorting and by whole-cell binding assay (data not shown).

Monoclonal antibodies 4G8 and 6E10 against A β were purchased from Signet Laboratories (Dedham, MA). The carboxyl end-specific polyclonal anti-A β_{40} and anti-A β_{42} were purchased from Calbiochem. The polyclonal antibody against mouse TMEFF1 was purchased from Santa Cruz Biotechnology (Dallas, TX). Highly cross-adsorbed Alexa Fluor-488 or 594-conjugated F(ab')₂ fragments of anti-mouse or anti-goat IgG (H + L) were from Molecular Probes (Eugene, OR, USA). Affinity purified goat anti-mouse and anti-goat IgG (H + L) conjugated to horseradish peroxidase were from Jackson Laboratories (Ben Harbor, ME). The polyclonal antibodies specific for the secreted forms of A β PP, which are A β PP α released by α -secretase and A β PP β released by β -secretase, were provided by Dr. Inhee Mook-Jung at the Seoul National University College of Medicine. Spin-labeled A β_{1-40} containing the TOAC nitroxide at position 26 was synthesized as previously described [20, 21].

TR cDNA construct and expression

The TR cDNA clone was purchased from Open Biosystems (clone#23671). For mammalian expression, the PCR fragment obtained using TOPO sequence containing primer set (5'-CAC CAT GGT GCT GTG GGA GTC C-3'/5'-GAT TAA CCT CGT GGA CGC-3') was cloned into pcDNA3.1-Directional TOPO Expression vector (Invitrogen). The accuracy of the TOPO/PCR cloning was later confirmed by sequencing. The TR-expressing plasmid was transiently transfected into N2a or N2a-A β PP cells using Lipofectamine LTX and Plus reagent (Invitrogen). For bacterial expression, the PCR fragment obtained using TOPO sequence containing primer sets (5'-C ACC TGC TCT GGT TAT GAT GAC AGA-3' paired with 5'-TCA TTC ACA GTG TTG TCC AGT ATA AC-3' or 5'-TCA TTC TCT GGC ACT TTC TTC TAA-3' to generate TR#2 or TR#3, respectively, see Fig. 1) was cloned into pET100/D-TOPO vector (Invitrogen) and the accuracy of the cloning was confirmed by sequencing. BL21 cells were transformed with the plasmids and protein expression was induced by Isopropyl β -D-1-thiogalactopyranoside (IPTG). Expressed TR fragments were purified using HiTrap 1 ml Chelating HP column (Pharmacia Inc.) charged with 0.1 M NiSO₄. Briefly, BL21 cells harboring TR plasmids were cultured overnight in 3 ml of LB medium and then transferred to new LB medium with 500 μ M of IPTG. The cells were cultured with shaking at 37° for 4 h. The cells were harvested and lysed with Guanidinium Lysis Buffer (Probond Purification System, Invitrogen). Lysates were passed through HiTrap 1 ml Chelating HP column and TR fragments were eluted using His-Select Elution Buffer (Sigma). Imidazole was removed by dialysis and TR fragments were concentrated using Vivaspin4 10K MWCO (Sartorius, Goettingen, Germany).

Cell cultures

MC65 human neuroblastoma cells were grown in the presence of 1 µg/ml tetracycline (TC) as described [22, 23]. The cell toxicity was induced by the removal of TC to induce expression of AβPP-C99 (the carboxyl 99 amino acids of AβPP which gives rise to Aβ after cleavage by β-secretase). To do so, the cells were washed extensively, and plated at a density of $1.2\text{--}1.5 \times 10^5$ cells/cm² in Opti-MEM (without phenol-red) from Gibco/BRL (Carlsbad, CA) without serum and without TC. The N2a-AβPP neuroblastoma line expressing AβPP with the Swedish mutation was a gift from Dr. Sangram Sisodia at University of Chicago. The preparation of cell homogenates and western blotting were performed as previously described [23, 24].

5xFAD mice

All experimental protocols were carried out with approval from the Institutional Animal Care and Use Committee of the University of California Davis. The line Tg6799 5xFAD mice co-express human AβPP695 with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) mutations and human PS1 harboring M146L and L286V mutations was obtained from Dr. Robert Vassar at Northwestern University [25]. Mice were sacrificed and their brains were cut in half sagittally. The left hemispheres were snap frozen. The right hemispheres were fixed in 4% paraformaldehyde for immunohistochemical studies.

Co-immunoprecipitation

To determine the co-immunoprecipitation (co-IP) of AβPP or Aβ with TR, cells were lysed in 300 µL of co-IP buffer (0.5% Triton X-100/in Tris-buffered saline, pH 7.4) containing protease inhibitors for 30 min at 4°. After centrifugation at 10,000× g for 15 min, the lysates (supernatants) were pre-cleared with Protein G-Sepharose CL-4B and subsequently were incubated with anti-TR, anti-Aβ, or anti-AβPP antibody overnight at 4°C. The resulting immunocomplexes were precipitated by Protein G-Sepharose CL-4B. In some experiments, the protein complexes were pulled down by anti-His antibody conjugated beads or glutathione sepharose GS4B agarose beads (Pharmacia) following the manufacturer's protocol. Beads were washed four times (5 min each) at 4° with co-IP buffer before elution. Eluted proteins were separated by SDS-PAGE, followed by immunoblotting with specified antibodies and Enhanced Chemiluminescent (ECL) reagents (Amersham Pharmacia Biotech, Inc., Piscataway, NJ).

Preparation of unaggregated and oligomeric Aβ solutions

Solutions of seedless, unaggregated Aβ and oligomeric, non-fibrillar Aβ were prepared according to established protocols [9, 26]. Briefly, dried Aβ peptides were first dissolved in ddH₂O with 0.1% trifluoroacetic acid (TFA). The solution was dialyzed against 0.1% TFA and lyophilized. Lyophilized peptides were then completely dissolved in hexafluoroisopropanol (HFIP) at room temperature for 1–3 h and lyophilized. The resulting Aβ film was dissolved with DMSO and stored at –20°. To generate unaggregated (mostly monomeric) Aβ solutions, the Aβ stock in DMSO was diluted directly into PBS. To make oligomers, the 10 µM unaggregated Aβ solution was incubated at 4° for 48 h with stirring at

300 RPM. The resulting oligomers were verified by atomic force microscopy as described [23], aliquoted, and stored at -20° .

Surface plasmon resonance spectroscopy (SPR)

The method to determine the binding kinetics between TR in the flow phase and A β O(1-42) immobilized on the SPR sensor chip was described in detail in a previous article [27].

Electron paramagnetic resonance spectroscopy (EPR) of spin-labeled A β

EPR measurements were carried out in a JEOL TE-100 X-band spectrometer (JEOL USA, Peabody, MA) fitted with a loop-gap resonator Molecular Specialties, Milwaukee, WI). A fresh stock of A β in DMSO was prepared as described above. A solution of mostly unaggregated (monomers and small oligomers) A β was then prepared by diluting the peptide stock to a final concentration of 10 μ M into either PBS or PBS containing 10 μ M of the TR fragment. Immediately after mixing, approximately 5 μ l of the sample was loaded into a sealed quartz capillary tube and scanned by EPR. The spectra were obtained by averaging three 2-min scans with a sweep width of 100 G at a microwave power of 2 mW and modulation amplitude of 1 G. All the spectra were recorded at room temperature.

Immunofluorescent staining and confocal microscopy

Immunofluorescence labeling and confocal microscopy for A β -immunoreactive aggregates and TR were performed according to our published protocols [23].

Gene silencing by RNA interference

RNAi plasmids (shRNAmir) designed to knock down TR expression and for control transfection were purchased from Open Biosystems. For transfection, cells were plated onto six-well plates and transfected with 2.5 μ g of shRNAmir using 12 μ L of lipofectamine LTX and Plus reagent (Invitrogen, Carlsbad, CA) for 48 h.

Statistics

We examined the statistical significance of differences between groups by applying one-way analysis of variance (ANOVA) with *post-hoc* Tukey test or Bonferroni tests, using the SigmaStat 3.1 (Systat Inc. Point Richmond, CA) software program.

RESULTS

TR interacts with A β

We immunoprecipitated intracellular A β from the MC65 human neuroblastoma cells and used mass spectrometry to identify co-immunoprecipitated proteins. In MC65 cells, the expression of A β PP-C99 and subsequent generation of A β was controlled by a promoter activated by withdrawal of TC from the medium. The MC65 culture has been used as a model of neuronal death due to accumulation of intraneuronal A β [23, 28], which might play a significant role in the early stage of amyloid cascade in AD [29–31]. Relevant to AD, the intracellular A β in MC65 cells aggregates into SDS-stable dimeric, trimeric, and tetrameric units [23], confirmed by mass spectroscopic analysis [32]. These oligomers

(A β O) were immunoreactive to A11 [23], an antibody recognizing specifically the conformation of prefibrillary oligomers [26], and anti-A β ₄₀, an antibody specific to the carboxyl end of A β ₁₋₄₀ [23]. The induced generation of A β O in MC65 cells eventually leads to cell death in three days. We lysed MC65 cells in 1% CHAPSO at 24 h after the induction of A β generation but prior to the starting of cytotoxicity, and immunoprecipitated A β and associated proteins with the 6E10 (anti-A β ₃₋₈) antibody. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of the immunoprecipitate revealed several non-A β proteins. Among them, TR, a predominantly brain and prostate protein, gave the most significant MASCOT scores. TR was previously found extensively in amyloid plaques [33], therefore was studied further.

We confirmed the association of A β and TR by determining if A β is present in the anti-TR immunoprecipitate from MC65 cell lysate. We used two TR-specific antibodies. 48G2 is a monoclonal antibody that recognizes the ectodomain of TR and its specificity has been extensively characterized by SPR, fluorescence-activated cell sorting, and whole-cell binding assays (see Methods). The second one was a commercially available affinity-purified goat anti-human polyclonal antibody. Both antibodies yielded essentially identical results. Figure 2A shows that A β dimer and trimer were present in the anti-TR immunoprecipitate obtained from the MC65 cell lysate. The identification of these A β immunoreactive bands in MC65 cells as SDS-stable oligomeric A β was previously confirmed [23, 32]. The MC65 cell lysate also contained A β tetramer; however, its presence in the anti-TR immunoprecipitate could not be certain because its corresponding band was masked by the immunoglobulins. In contrast, the immunoprecipitates of pre-immune goat IgG and IgG recognizing TMEFF-1, a related protein also enriched in the brain [19], did not contain A β , supporting the specificity of our assay.

We previously showed that the neurotoxic events in MC65 cells come from intracellular accumulation of A β ₄₀ immunoreactive A β O [23]. Co-immunostaining of MC65 cells with anti-TR and anti-A β ₄₀ at 24 h after A β induction showed that TR also colocalized with the aggregates of A β O (Fig. 2B, arrow). In contrast, in control MC65 cells without A β induction, anti-TR stained a fine cytoplasmic granular profile, while anti-A β ₄₀ did not show any positive staining (Fig. 2B, upper panels). This result is consistent with an interaction of TR with A β . The granular cytoplasmic rather than a membrane profile of TR immunoreactivity is consistent with previous results in adult human, mouse, and cat neurons [33, 34], and suggests rapid internalization of TR in neuronal cells [18].

To determine if TR also interacts with synthetic A β ₁₋₄₂, the other major species of A β deposited in AD brains, we expressed in N2a neuroblastoma cells a recombinant TR protein with a C-terminal V5/His tag (TR-V5/His), which consists of simian virus 5/poly-histidine residues to facilitate protein identification and isolation by specific anti-V5 and anti-His antibodies. N2a cells expressing LacZ-V5/His were used as a negative control. After incubating the extracts of the two groups of cells with synthetic A β ₁₋₄₂ in the presence of 1% CHAPSO, we pulled down TR with anti-His beads and the immunoprecipitates were analyzed by 6E10 western blotting. As shown in Fig. 2C, A β ₁₋₄₂ was clearly pulled down by TR-V5/His but not by the negative control LacZ-V5/His.

TR co-localizes with amyloid plaques, intraneuronal A β , and reactive astrocytes in the AD model 5xFAD mice

Neurons in 5xFAD mice were engineered to generate a large quantity of A β ₁₋₄₂, which results in robust A β accumulation and aggregation in the brain [25]. At three months of age, the mice demonstrate numerous small amyloid plaques as well as neurons with cytoplasmic A β aggregates including A β O [35]. Immunohistochemical studies showed that TR colocalized extensively with amyloid plaques (Fig. 3A, B). In addition, TR was localized to cytoplasm of neurons, which were also immunoreactive to anti-A β ₄₂. In contrast, all neurons without intraneuronal A β ₄₂ invariably had low to non-detectable immunoreactivities to anti-TR (Fig. 3B). Because anti-A β ₄₂ only recognizes peptides with A β ₄₂ carboxyl terminal ends, its intraneuronal immunoreactivity does not represent A β PP or other non-A β ₄₂ A β PP metabolites. Rather, those neurons with intensive A β ₄₂ immunoreactivity were those with intraneuronal A β ₄₂ accumulation and aggregation (Fig. 3B, lower panel). This result indicates an upregulation of TR expression in neurons with intraneuronal A β . This result also suggests association between TR and A β *in vivo*. In addition, anti-TR immunostained curvilinear processes that appeared to be associated with amyloid plaques (Fig. 3A, B). Double immunostaining for TR and the astrocytic marker GFAP revealed that these were processes of reactive astrocytes that were not seen in non-amyloid regions in 5xFAD mice and not seen in all brain regions of the wild-type littermates (Fig. 3C).

TR directly binds A β in solution

The above data suggest that TR is physically associated with A β in extracellular amyloid plaques and in intraneuronal compartments. We asked whether TR directly binds A β . For this purpose, we employed a sensitive SPR method with which the binding between TR in the flow phase and the A β O(1-42) immobilized on the sensor chip can be analyzed in real time, as previously described [27]. The size and neurotoxic properties of our A β O(1-42) preparations were analyzed by atomic force microscopy and cell-based neurotoxic assays, as previously described. The result showed that the TR segment containing the extracellular domain (ectodomain) (TR#2 in Fig. 1) directly binds A β O with a high affinity (K_D = 76.8 nM). The binding is only slightly weaker than ApoE (K_D = 23.4 nM), a protein known to directly bind A β and its oligomers [20, 36]. The negative control protein ovalbumin showed no binding to A β O (Fig. 4).

To further investigate the direct interaction between A β and TR, we performed EPR spectroscopy to observe the conformational dynamics of the A β peptide as a function of TR binding [35, 37]. EPR signals were analyzed from a TOAC nitroxide probe targeted specifically to the 26th residue within the loop domain of A β [20]. A β containing spin-labeled peptide was previously shown to have a comparable degree of toxicity to N2A cells and a similar particle size distribution as the unlabeled A β [20]. We therefore examined whether alteration in the dynamics of the spin-labeled A β could provide indication of interaction between the peptide and the recombinant TR extracellular domain (TR#2 in Fig. 1). Our experiment analyzed A β in its nascent state, consisting of monomers and small oligomers by introducing A β to a final concentration of 10 μ M followed by EPR scanning. The EPR results are shown in Fig. 5. In the absence of TR, the EPR spectrum shows a sharp line shape with a correlation time of 1 ns or less, consistent with a small disordered A β

species [20, 21]. In the presence of TR, however, the EPR spectrum is broadened, indicating a decreased rotational correlation time of the imbedded spin-label. Given the obligate low spin concentrations of these samples, broad features are difficult to resolve in the spectra. Nevertheless, the broadening of the A β spectrum upon TR addition appears largely homogeneous. Thus in addition to a restriction in rotational dynamics upon TR binding, a dipolar relaxation among flexible labels likely contributes to the spectral broadening [38]. This suggests that much of the TR-bound peptide in these experiments is in the oligomeric state, with a conformation that maintains the TOAC labels within a close proximity. While we cannot quantitatively ascribe the broadening contributions among a reduction in spin label correlation time, an increase in dipolar spin interaction, or a combination of both, the change in the A β EPR spectrum provides evidence for a physical interaction between A β and the TR extra-cellular domain.

TR also binds A β PP and modulates α -secretase processing of A β PP

Although we started with the goal to search for binding partners for A β O, we found that A β PP was also immunoprecipitated by anti-TR, but not by negative control immunoglobulins (Fig. 2A). We confirmed this association by further co-immunoprecipitation experiments using N2a cells. First, we transfected N2a-A β PP cells, a permanent line of N2a overexpressing A β PP, with plasmids expressing TR-V5/His or LacZ-V5/His, lysed the cells, and incubated the lysates with anti-His beads to pull down the expressed proteins. As shown in Fig. 6A, A β PP was co-immunoprecipitated with TR but not with LacZ. This association should involve the full length or at least the carboxyl segments of TR because the engineered V5/His sequence was located at the carboxyl terminus. A β was not co-immunoprecipitated because N2a-A β PP cells generate little amount of A β . Next, we examined if full-length A β PP can also pull down TR. We transfected N2a cells (expressing little endogenous A β PP) with a plasmid expressing TR-V5/His or LacZ-V5/His, lysed the cells, and incubated the lysates with recombinant GST-A β PP (expressing full length A β PP) in the presence of 1% CHAPS. GST-A β PP and associated proteins were subsequently pulled down using GS4B agarose beads. Western blotting with the anti-V5 antibody showed that A β PP pulled down proteins of 50–56 kDa. These likely represent the full-length TR (predicted molecular weight of the core peptide: 38 kDa) with various N-linked glycosylation and other post-translational modifications, as shown previously [14]. In addition, there was a small carboxyl-terminal fragment of TR (CTF-TR), which may correspond to the transmembrane and cytoplasmic domain of TR after the shedding of the ectodomain (predicted molecular weight: 8 kDa) (Fig. 6B).

Due to the association of cellular A β PP with TR, especially that the metalloproteinase ADAM17 that cleaves TR also functions as an α -secretase to cleave A β PP, we asked if expression of TR alters A β PP metabolism. Figure 6C and D shows that plasmid-directed expression of TR in N2a-A β PP cells increased the level of the secreted ectodomain of A β PP cleaved by α -secretase (sA β PP α), while downregulation of TR by a siRNA decreased the level of sA β PP α in the conditioned medium. We also evaluate the influence of TR expression on the level of sA β PP β (the secreted ectodomain of A β PP cleaved by β -secretase) but did not find significant changes following alterations of TR expression (data not shown).

TR protects neurons from A β -induced toxicity

A β -induced neurotoxicity has been widely accepted as a central event in AD pathogenesis. In particular, accumulating evidence supports that A β O is likely the most toxic species. Because TR directly interacts with A β O, we asked if the presence of TR alters A β neurotoxicity. N2a cells have been a widely used model for testing A β O toxicity [9] and was used to evaluate the effect of TR. Overexpression of TR in N2a cells almost completely protected neurons from death induced by A β O added to the culture media. In contrast, when the endogenous TR was downregulated to 20–30% of the control level by a siRNA (Fig. 6C), the A β O-induced neuronal death was significantly enhanced (Fig. 7A). This result indicates that TR is able to blocks A β O-induced neurotoxicity, likely via its interaction with A β O. The mechanism for this protective effect may include binding of A β O to TR on the cell surface or to TR released into the medium, because we also detected an increased level of TR in the conditioned medium of N2a after overexpressing TR (Fig. 7B). Indeed, co-application of two recombinant TR extra-cellular segments, TR#2 and TR#3 (Fig. 1), with A β O to the culture medium also blocked A β O-induced neuronal death. Co-application of a negative control protein ovalbumin showed no such effect (Fig. 7C). Because the EGF-like domain in TR#2 conferred no additional protective effect compared to TR#3 without this domain, this result suggests that the amino acid sequence N-terminal to the EGF-like domain is required for neuroprotection.

DISCUSSION

Proteins of different functional categories have been found to bind A β in the extracellular or intracellular milieu and mediate various cellular effects of A β . These include apolipoproteins, membrane receptors, extracellular matrix components, molecular chaperons, adhesion molecules, and intracellular enzymes. A large majority of these identified A β -binding proteins were shown to be required for neurotoxicity. Examples of putative membrane receptors mediating A β neurotoxicity include the receptor for advanced glycation end products (RAGE) [39], the α 7 nicotinic acetylcholine receptor (nAChR α 7) [40], cellular prion protein [41, 42], and interestingly, A β PP, the precursor of A β [43]. TR, similar to A β PP, is a type I transmembrane protein; our data imply that it could also serve as a membrane receptor for A β aggregates. Also similar to A β PP, the secreted ectodomain of TR can bind to A β aggregates. Moreover, TR binds full-length A β PP and modulates α -secretase processing of A β PP. This binding might involve residues of TR carboxyl to the ectodomain because a CTF-TR fragment was also pulled down by A β PP (Fig. 6B). However, immunoprecipitation of TR, either ectodomain or full-length, failed to pull down A β PP-C99 (Figs. 2 and 6) which spans the transmembrane and cytoplasmic domains of A β PP, even in the MC65 line overexpressing A β PP-C99. It is possible that the conformation and cellular compartmentalization of A β PP-C99 may be different from the full-length A β PP and therefore preclude its binding to TR. Further studies are required to delineate the mechanisms of binding between TR and A β as well as between TR and A β PP.

Distinct from A β PP and all the above putative A β receptors which mediate A β toxicity, TR is unique in its ability to protect neurons from A β toxicity. Our data suggest that neuroprotection is likely due to the ability of TR to bind A β O with a high affinity and

neutralize A β O toxicity. Alternatively, TR could inhibit A β oligomer or fibril formation, which is not explored here. The other possible mechanisms of neuroprotection include the neurotrophic actions of the secreted ectodomain of TR and sA β PP α , the production of which can be enhanced by expression of TR. The finding that TR is physically associated with cellular A β PP and TR expression enhances α -secretase cleavage of A β PP can have two implications. First, because α -secretase cleaves A β PP in the middle of the A β sequence to preclude the production of A β , TR expression may therefore reduce A β production. Our ELISA method was not sensitive enough to measure the small amount of A β released by N2a-A β PP cells and more sensitive methods are needed to address this possibility. Second, because ADAM17 as an α -secretase cleaves both A β PP and TR, TR could serve as an anchor for α -secretase processing of A β PP. Our results should prompt further studies on the mechanisms of TR-A β /TR-A β PP interactions.

Most studies regarding TR functions so far have been concerned with its role in tumor growth because of its overexpression in prostate cancer and a variety of other cancers. The differential roles of holo-TR and secreted TR ectodomain in regulating prostatic cancer growth were reported [44]. In contrast, except for the observation that the ectodomain of TR increased survival of cultured hippocampal and mesencephalic neurons [16], little is known about the function of TR in the nervous system. Using subtractive hybridization, Siegel et al. identified TR as one of the two genes possibly related to initiation of primary dendrites seen in normal newborn and a model of GM2 gangliosidosis [34]. TR knockout mice were born normal, but showed growth retardation and died around weaning age. However, no structural abnormalities in the brain, the spinal cord, the enteric nervous system, or the prostate were found to explain the premature death [45]. Relevant to AD, TR immunoreactivity was found extensively within individual amyloid plaques and pervasively in plaques throughout human AD cortices [33], consistent with our findings in 5xFAD mice, further supporting the physical association of TR with A β aggregates. Intriguingly, the same investigators failed to show TR immunoreactivity in the plaques of a line of presenilin-1 (PS1)/A β PP mouse model of AD [33], indicating that some PS1/A β PP models may not have amyloid plaques fully representing those of humans.

A β deposition appears to enhance TR expression in reactive astrocytes. This could provide an interesting non-neuronal mechanism to regulate A β metabolism and toxicity. Two proinflammatory cytokines, tumor necrosis factor- α (TNF- α) and interleukin-1 β (IL-1 β), were shown to induce release of the TR ectodomain by A172 human glioma cells, which suggests a role of TR in tissue growth and repair following neuroinflammation [46]. The A β -initiated neuroinflammation is known to produce TNF- α and IL-1 β ; this, together with overexpression of TR in astrocytes, would lead to increased extracellular level of TR ectodomain, which would bind A β O with a high affinity. This mechanism could contribute to neutralization of A β toxicity, enhanced internalization of A β , and amyloid plaque formation. In summary, our data provide the first line of evidence to suggest that TR is a brain-enriched endogenous modulator of A β neurotoxicity and an enhancer of α -secretase processing of A β PP.

Acknowledgments

This work was supported by the UC Davis Alzheimer's Disease Center (AG010129), and NIH grants AG025500 and AG031362.

Authors' disclosures available online (<http://j-alz.com/manuscript-disclosures/15-0318r1>).

References

1. Masters CL, Selkoe DJ. Biochemistry of Amyloid beta-Protein and Amyloid Deposits in Alzheimer Disease. *Cold Spring Harb Perspect Med*. 2012; 2:a006262. [PubMed: 22675658]
2. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. *Annu Rev Neurosci*. 2003; 26:267–298. [PubMed: 12704221]
3. Necula M, Kaye R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. *J Biol Chem*. 2007; 282:10311–10324. [PubMed: 17284452]
4. Glabe CG. Structural classification of toxic amyloid oligomers. *J Biol Chem*. 2008; 283:29639–29643. [PubMed: 18723507]
5. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from A β 1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A*. 1998; 95:6448–6453. [PubMed: 9600986]
6. Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature*. 2006; 440:352–357. [PubMed: 16541076]
7. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med*. 2008; 14:837–842. [PubMed: 18568035]
8. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein assembly and Alzheimer disease. *J Biol Chem*. 2009; 284:4749–4753. [PubMed: 18845536]
9. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. *J Biol Chem*. 2002; 277:32046–32053. [PubMed: 12058030]
10. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. *J Neurosci*. 2004; 24:10191–10200. [PubMed: 15537891]
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*. 2002; 297:353–356. [PubMed: 12130773]
12. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry*. 2000; 39:10831–10839. [PubMed: 10978169]
13. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of A β . *Am J Pathol*. 2006; 168:184–194. [PubMed: 16400022]
14. Uchida T, Wada K, Akamatsu T, Yonezawa M, Noguchi H, Mizoguchi A, Kasuga M, Sakamoto C. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. *Biochem Biophys Res Commun*. 1999; 266:593–602. [PubMed: 10600548]
15. Ali N, Knauper V. Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. *J Biol Chem*. 2007; 282:37378–37388. [PubMed: 17942404]

16. Horie M, Mitsumoto Y, Kyushiki H, Kanemoto N, Watanabe A, Taniguchi Y, Nishino N, Okamoto T, Kondo M, Mori T, Noguchi K, Nakamura Y, Takahashi E, Tanigami A. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. *Genomics*. 2000; 67:146–152. [PubMed: 10903839]
17. Heanue TA, Pachnis V. Expression profiling the developing mammalian enteric nervous system identifies marker and candidate Hirschsprung disease genes. *Proc Natl Acad Sci U S A*. 2006; 103:6919–6924. [PubMed: 16632597]
18. Zhao XY, Liu HL, Liu B, Willuda J, Siemeister G, Mahmoudi M, Dinter H. Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. *Transl Oncol*. 2008; 1:102–109. [PubMed: 18633458]
19. Kanemoto N, Horie M, Omori K, Nishino N, Kondo M, Noguchi K, Tanigami A. Expression of TMEFF1 mRNA in the mouse central nervous system: Precise examination and comparative studies of TMEFF1 and TMEFF2. *Brain Res Mol Brain Res*. 2001; 86:48–55. [PubMed: 11165370]
20. Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, Jin LW, Voss JC. A differential association of Apolipoprotein E isoforms with the amyloid-beta oligomer in solution. *Proteins*. 2011; 79:402–416. [PubMed: 21069870]
21. Petrlova J, Kalai T, Maezawa I, Altman R, Harishchandra G, Hong HS, Bricarello DA, Parikh AN, Lorigan GA, Jin LW, Hideg K, Voss JC. The influence of spin-labeled fluorene compounds on the assembly and toxicity of the abeta peptide. *PLoS One*. 2012; 7:e35443. [PubMed: 22558151]
22. Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, Montine KS. Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. *J Neurochem*. 2004; 91:1312–1321. [PubMed: 15584908]
23. Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, Iwamoto T, Radke GA, Pettersson E, Martin GM, Hua DH, Jin LW. A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. *J Neurochem*. 2006; 98:57–67. [PubMed: 16805796]
24. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. *Am J Pathol*. 2004; 164:975–985. [PubMed: 14982851]
25. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. *J Neurosci*. 2006; 26:10129–10140. [PubMed: 17021169]
26. Kaye R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*. 2003; 300:486–489. [PubMed: 12702875]
27. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, LaFerla FM, Jin LW. Congo red and thioflavin-T analogs detect Abeta oligomers. *J Neurochem*. 2008; 104:457–468. [PubMed: 17953662]
28. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. *J Neurochem*. 2008; 105:1336–1345. [PubMed: 18208543]
29. Querfurth HW, LaFerla FM. Alzheimer's disease. *N Engl J Med*. 2010; 362:329–344. [PubMed: 20107219]
30. Wirths O, Bayer TA. Intraneuronal Abeta accumulation and neurodegeneration: Lessons from transgenic models. *Life Sci*. 2012; 91:1148–1152. [PubMed: 22401905]
31. Gouras GK, Willen K, Tampellini D. Critical role of intraneuronal Abeta in Alzheimer's disease: Technical challenges in studying intracellular Abeta. *Life Sci*. 2012; 91:1153–1158. [PubMed: 22727791]
32. Woltjer RL, Nghiem W, Maezawa I, Milatovic D, Vaisar T, Montine KS, Montine TJ. Role of glutathione in intra-cellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. *J Neurochem*. 2005; 93:1047–1056. [PubMed: 15857408]
33. Siegel DA, Davies P, Dobrenis K, Huang M. Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. *J Neurochem*. 2006; 98:34–44. [PubMed: 16805794]

34. Siegel DA, Huang MK, Becker SF. Ectopic dendrite initiation: CNS pathogenesis as a model of CNS development. *Int J Dev Neurosci*. 2002; 20:373–389. [PubMed: 12175877]
35. Hong HS, Maezawa I, Budamagunta M, Rana S, Shi A, Vassar R, Liu R, Lam KS, Cheng RH, Hua DH, Voss JC, Jin LW. Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents. *Neurobiol Aging*. 2010; 31:1690–1699. [PubMed: 19022536]
36. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A*. 1993; 90:1977–1981. [PubMed: 8446617]
37. Hubbell WL, Cafiso DS, Altenbach C. Identifying conformational changes with site-directed spin labeling. *Nat Struct Biol*. 2000; 7:735–739. [PubMed: 10966640]
38. McHaourab HS, Oh KJ, Fang CJ, Hubbell WL. Conformation of T4 lysozyme in solution. Hinge-bending motion and the substrate-induced conformational transition studied by site-directed spin labeling. *Biochemistry*. 1997; 36:307–316. [PubMed: 9003182]
39. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. *Nature*. 1996; 382:685–691. [PubMed: 8751438]
40. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. *J Biol Chem*. 2000; 275:5626–5632. [PubMed: 10681545]
41. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. *Nature*. 2009; 457:1128–1132. [PubMed: 19242475]
42. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. *Nat Neurosci*. 2012; 15:1227–1235. [PubMed: 22820466]
43. Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA. Amyloid beta interacts with the amyloid precursor protein: A potential toxic mechanism in Alzheimer's disease. *Nat Neurosci*. 2000; 3:460–464. [PubMed: 10769385]
44. Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarria MJ. The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. *J Biol Chem*. 2011; 286:16091–16100. [PubMed: 21393249]
45. Chen TR, Wang P, Carroll LK, Zhang YJ, Han BX, Wang F. Generation and characterization of Tmeff2 mutant mice. *Biochem Biophys Res Commun*. 2012; 425:189–194. [PubMed: 22828515]
46. Lin H, Wada K, Yonezawa M, Shinoki K, Akamatsu T, Tsukui T, Sakamoto C. Tomoregulin ectodomain shedding by proinflammatory cytokines. *Life Sci*. 2003; 73:1617–1627. [PubMed: 12875894]

Fig. 1.

Schematic illustrations of the TR domain structure in relation to the amino acid number and the expression constructs used in this study. EGF, epidermal growth factor; FS-1, follistatin-like domain 1; FS-2, follistatin-like domain 2; TM, transmembrane domain.

Fig. 2.

TR is associated with Aβ. A) MC65 cells were induced to express Aβ by withdrawal of TC from the medium for 24 h and were lysed with a lysis buffer containing 1% CHAPS. The lysates were immunoprecipitated with goat IgG (non-specific control), anti-TMEFF1, or anti-TR (goat polyclonal). The lane labeled “Input” contained the input MC65 lysate without immunoprecipitation by an antibody. The immunoprecipitated proteins were analyzed by Western blotting using 6E10. Aβ dimer, Aβ trimer, and AβPP were co-immunoprecipitated with TR. The non-specific bands around 28 kDa in the first three lanes represent antibody components such as the light chain of IgG, which were not present in the Input lane. B) MC65 cells were cultured in the presence of TC (+TC) or were induced to express Aβ (–TC) for 24 h and were doubly immunostained with anti-TR (green) and anti-Aβ₄₀ (red), and counterstained with DAPI (blue). Representative fluorescent images of cells are shown. Arrows point to Aβ₄₀-positive intraneuronal Aβ aggregates in –TC cells, which were also heavily stained with anti-TR. C) Extracts of N2a cells mock transfected, transfected with TR-V5/His or LacZ-V5/His were incubated with Aβ₁₋₄₂ in the presence of 1% CHAPSO. The recombinant proteins and associated proteins were then pulled down by anti-His beads. Western blot (WB) using 6E10 showed that Aβ₁₋₄₂ was pulled down together with recombinant TR.

Fig. 3.

TR is associated with amyloid plaques and intraneuronal A β , and is expressed in reactive astrocytes in 5xFAD mice. A) Cortical sections of 5xFAD and age-matched wild-type littermate mice were co-immunostained with anti-A β ₄₂ and anti-TR. Scale bar = 100 μ m. B) Three TR-immunoreactive structures are indicated: Arrows: amyloid plaques; Filled arrowheads: neurons with intraneuronal A β ; and Empty arrowheads: curvilinear profiles. Scale bar = 50 μ m. The lower panel shows magnified images of a neuron with intraneuronal A β in comparison to one without. C) Co-immunostaining with anti-TR and anti-GFAP showed that the TR-positive curvilinear profiles were processes of reactive astrocytes in the neighborhood amyloid plaques.

Fig. 4.

The ectodomain of TR binds A β O with a high affinity. ApoE, TR#2, and ovalbumin applied to the flow phase and their binding to A β O (prepared from the peptide A β_{1-42}) immobilized on the chip was analyzed in real time. Shown are representative SPR response curves elicited by indicated protein ligands with a series of concentrations. RU, Response Unit.

Fig. 5. EPR spectra of spin-labeled A β (10 μ M) in the absence (black trace) and presence (red trace) of the TR ectodomain TR#2 (10 μ M). Shown is a scan over a magnetic field of 100 G.

Fig. 6.

TR is associated with AβPP and affects the level of sAβPPα. A) N2a-AβPP cells were mock-transfected (Mock), transfected with TR-V5/His or with LacZ-V5/His. The recombinant proteins and associated proteins in the cell extracts were then pulled down by anti-His beads. Western blot (WB) using 6E10 showed that AβPP was pulled down together with recombinant TR. B) Extracts of N2a cells mock transfected, transfected with TR-V5/His or LacZ-V5/His were incubated with GST-AβPP. The recombinant GST-AβPP and associated proteins were then pulled down by GS4B agarose beads. WB using anti-V5 showed that two TR-related proteins were pulled down together with AβPP, which correspond to the full-length (FL-TR) and a C-terminal fragment (CTF-TR) of TR. C) N2a-

A β PP cells were mock-transfected, transfected with a TR-expressing plasmid, a control siRNA, or a siRNA specific to TR to downregulate TR. The level of sA β PP α in the 24-h conditioned medium was evaluated by WB using an antibody specific to sA β PP α . The level of TR transcript was estimated by RT-PCR. D) The bar graph shows the band intensity of sA β PP α in each condition adjusted by the respective band intensity of β -actin and then normalized to that of mock transfection (Mock) in the WB. $n = 3$, $*p < 0.05$ and $**p < 0.001$.

Fig. 7.

TR protects neurons from A β -induced neurotoxicity. A) N2a cells were mock-transfected, transfected with a TR-expressing plasmid, a control siRNA, or a siRNA specific to TR, and then treated with 1 μ M A β O(1-42) for 24 h. Cell viability was evaluated by MTT assay and presented as % survival relative to solvent treated controls (set as 100% survival). B) The conditioned media (CM) from N2a cells transfected with the indicated plasmids were analyzed by western blot using anti-V5. TR fragments were abundantly present in the CM of cells expressing TR. C) N2a cells were treated with 1 μ M A β O(1-42) in the presence of the indicated proteins for 24 h. Cell viability was evaluated by MTT assay and presented as % survival relative to solvent treated controls (set as 100% survival). $n = 3$, * $p < 0.05$ and ** $p < 0.001$.